These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
228 related articles for article (PubMed ID: 24329807)
1. The preparation of VEGFR1/CD3 bispecific antibody and its specific cytotoxicity against VEGFR1-positive breast cancer cells. Tang P; Li L; Zhou Y; Shen CC; Kang YH; Yao YQ; Yi C; Gou LT; Yang JL Biotechnol Appl Biochem; 2014; 61(4):376-84. PubMed ID: 24329807 [TBL] [Abstract][Full Text] [Related]
2. Fully human HER2/cluster of differentiation 3 bispecific antibody triggers potent and specific cytotoxicity of T lymphocytes against breast cancer. Zhou Y; Gou LT; Guo ZH; Liu HR; Wang JM; Zhou SX; Yang JL; Li XA Mol Med Rep; 2015 Jul; 12(1):147-54. PubMed ID: 25760691 [TBL] [Abstract][Full Text] [Related]
3. A fully human CD19/CD3 bi-specific antibody triggers potent and specific cytotoxicity by unstimulated T lymphocytes against non-Hodgkin's lymphoma. Zhou Y; Gou LT; Mu B; Liao WC; He J; Ma C; Yao YQ; Yang JL Biotechnol Lett; 2012 Jul; 34(7):1183-91. PubMed ID: 22421972 [TBL] [Abstract][Full Text] [Related]
4. A Novel Bispecific Antibody against Human CD3 and Ephrin Receptor A10 for Breast Cancer Therapy. Taki S; Kamada H; Inoue M; Nagano K; Mukai Y; Higashisaka K; Yoshioka Y; Tsutsumi Y; Tsunoda S PLoS One; 2015; 10(12):e0144712. PubMed ID: 26678395 [TBL] [Abstract][Full Text] [Related]
5. Humanization of the bispecific epidermal growth factor receptor x CD3 diabody and its efficacy as a potential clinical reagent. Asano R; Sone Y; Makabe K; Tsumoto K; Hayashi H; Katayose Y; Unno M; Kudo T; Kumagai I Clin Cancer Res; 2006 Jul; 12(13):4036-42. PubMed ID: 16818703 [TBL] [Abstract][Full Text] [Related]
6. In vivo studies using bispecific antibodies (anti-CD3 x anti-idiotype) and CD28-induced costimulation in the BCL1 lymphoma. Demanet C; Brissinck J; De Jonge J; Thielemans K J Hematother; 1995 Oct; 4(5):363-8. PubMed ID: 8581370 [TBL] [Abstract][Full Text] [Related]
7. Cytokine-induced killer (CIK) cells bound with anti-CD3/anti-CD133 bispecific antibodies target CD133(high) cancer stem cells in vitro and in vivo. Huang J; Li C; Wang Y; Lv H; Guo Y; Dai H; Wicha MS; Chang AE; Li Q Clin Immunol; 2013 Oct; 149(1):156-68. PubMed ID: 23994769 [TBL] [Abstract][Full Text] [Related]
8. A novel asymmetrical anti-HER2/CD3 bispecific antibody exhibits potent cytotoxicity for HER2-positive tumor cells. Yu S; Zhang J; Yan Y; Yao X; Fang L; Xiong H; Liu Y; Chu Q; Zhou P; Wu K J Exp Clin Cancer Res; 2019 Aug; 38(1):355. PubMed ID: 31412896 [TBL] [Abstract][Full Text] [Related]
9. A T-cell-engaging B7-H4/CD3-bispecific Fab-scFv Antibody Targets Human Breast Cancer. Iizuka A; Nonomura C; Ashizawa T; Kondou R; Ohshima K; Sugino T; Mitsuya K; Hayashi N; Nakasu Y; Maruyama K; Yamaguchi K; Akiyama Y Clin Cancer Res; 2019 May; 25(9):2925-2934. PubMed ID: 30737243 [TBL] [Abstract][Full Text] [Related]
10. Evaluation of Fc gamma receptor mediated T-cell activation by two purified CD3 x CD19 bispecific monoclonal antibodies with hybrid Fc domains. Haagen IA; Geerars AJ; Bast EJ; de Gast GC; van de Winkel JG; de Lau WB Ther Immunol; 1994 Oct; 1(5):279-87. PubMed ID: 7584502 [TBL] [Abstract][Full Text] [Related]
11. Activation of T cell cytotoxicity against autologous common acute lymphoblastic leukemia (cALL) blasts by CD3xCD19 bispecific antibody. Csóka M; Strauss G; Debatin KM; Moldenhauer G Leukemia; 1996 Nov; 10(11):1765-72. PubMed ID: 8892680 [TBL] [Abstract][Full Text] [Related]
12. [Study on p53 tetramerization domain in improving functional affinity and biological activity of antibody]. Wang D; Wu GJ; Tan JM; Wang H Zhonghua Yi Xue Za Zhi; 2005 Feb; 85(7):479-82. PubMed ID: 15854555 [TBL] [Abstract][Full Text] [Related]
13. A bispecific diabody directed against prostate-specific membrane antigen and CD3 induces T-cell mediated lysis of prostate cancer cells. Bühler P; Wolf P; Gierschner D; Schaber I; Katzenwadel A; Schultze-Seemann W; Wetterauer U; Tacke M; Swamy M; Schamel WW; Elsässer-Beile U Cancer Immunol Immunother; 2008 Jan; 57(1):43-52. PubMed ID: 17579857 [TBL] [Abstract][Full Text] [Related]
14. Rearranging the domain order of a diabody-based IgG-like bispecific antibody enhances its antitumor activity and improves its degradation resistance and pharmacokinetics. Asano R; Shimomura I; Konno S; Ito A; Masakari Y; Orimo R; Taki S; Arai K; Ogata H; Okada M; Furumoto S; Onitsuka M; Omasa T; Hayashi H; Katayose Y; Unno M; Kudo T; Umetsu M; Kumagai I MAbs; 2014; 6(5):1243-54. PubMed ID: 25517309 [TBL] [Abstract][Full Text] [Related]
15. A tetravalent bispecific TandAb (CD19/CD3), AFM11, efficiently recruits T cells for the potent lysis of CD19(+) tumor cells. Reusch U; Duell J; Ellwanger K; Herbrecht C; Knackmuss SH; Fucek I; Eser M; McAleese F; Molkenthin V; Gall FL; Topp M; Little M; Zhukovsky EA MAbs; 2015; 7(3):584-604. PubMed ID: 25875246 [TBL] [Abstract][Full Text] [Related]
16. CEA/CD3 bispecific antibody MEDI-565/AMG 211 activation of T cells and subsequent killing of human tumors is independent of mutations commonly found in colorectal adenocarcinomas. Oberst MD; Fuhrmann S; Mulgrew K; Amann M; Cheng L; Lutterbuese P; Richman L; Coats S; Baeuerle PA; Hammond SA MAbs; 2014; 6(6):1571-84. PubMed ID: 25484061 [TBL] [Abstract][Full Text] [Related]
17. Retargeting T cells to GD2 pentasaccharide on human tumors using Bispecific humanized antibody. Xu H; Cheng M; Guo H; Chen Y; Huse M; Cheung NK Cancer Immunol Res; 2015 Mar; 3(3):266-77. PubMed ID: 25542634 [TBL] [Abstract][Full Text] [Related]
18. [Construction and expression of anti-CD3/anti-prostate-cancer bispecific single-chain antibody]. Wang D; Wu GJ; Wang H; Yang SL; Wu WZ; Xu TZ; Tan JM Zhonghua Yi Xue Za Zhi; 2003 Aug; 83(15):1292-5. PubMed ID: 12930679 [TBL] [Abstract][Full Text] [Related]
19. Nanocell targeting using engineered bispecific antibodies. Taylor K; Howard CB; Jones ML; Sedliarou I; MacDiarmid J; Brahmbhatt H; Munro TP; Mahler SM MAbs; 2015; 7(1):53-65. PubMed ID: 25523746 [TBL] [Abstract][Full Text] [Related]
20. MUC1-specific targeting immunotherapy with bispecific antibodies: inhibition of xenografted human bile duct carcinoma growth. Katayose Y; Kudo T; Suzuki M; Shinoda M; Saijyo S; Sakurai N; Saeki H; Fukuhara K; Imai K; Matsuno S Cancer Res; 1996 Sep; 56(18):4205-12. PubMed ID: 8797593 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]